Article

Next generation of anti-PD-L1 Atezolizumab with better anti-tumor efficacy <i>in vivo</i>

2020-07-01

Abstract excerpt

Some cancer patients treated with Atezolizumab, PD-L1 antibody drug launched by Genentech, quickly developed anti-drug antibody (ADA), led to loss of efficacy. This was likely due to the heavy aggregation of Atezolizumab, caused by mutation of N297A for removing unwanted antibody-dependent cytotoxicity (ADCC) of IgG1 antibody drug. Here, we developed a new version of Atezolizumab (Maxatezo), which was demonstrated...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c4714363-07e4-59e7-a472-a7641529986d
DOI: 10.1101/2020.06.30.166207

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Next generation of anti-PD-L1 Atezolizumab with better anti-tumor efficacy <i>in vivo</i>DOI 10.1101/2020.06.30.166207Read

Monoclonal antibodies: From magic bullet to precision weaponSemantic proximity Read

Anti-PD-1-iRGD Peptide Conjugate Boosts Antitumor Efficacy via Engagement Augmentation and Penetration Enhancement of T cellsSemantic proximity Read

Non-Clinical Evaluation of the Anti-PD-1 Antibody UDIZ-007Semantic proximity Read

Allelic Variation in<i>HLA-DRB1</i>is Associated with Development of Anti-Drug Antibodies in Cancer Patients Treated with Atezolizumab that are Neutralizing<i>in Vitro</i>Semantic proximity Read

Atezolizumab and Granzyme B as Immunotoxin Against PD-L1 Antigen; An Insilico StudySemantic proximity Read

Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable PatientsSemantic proximity Read

Cell-based production of Fc-GlcNAc and Fc-alpha-2,6 sialyl glycan enriched antibody with improved effector functions through glycosylation pathway engineeringSemantic proximity Read

Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1Semantic proximity Read

Clinical Potential of Antibody–Drug Conjugates in Early-Phase Clinical Trials for Late-Line Treatment of Advanced Solid TumorsSemantic proximity Read

Structural basis of a high-affinity antibody binding to glycoprotein region with consecutive glycosylation sitesSemantic proximity Read

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumabSemantic proximity Read

TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacySemantic proximity Read